[HTML][HTML] Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments

CA Maronese, MA Pimentel, MM Li… - American Journal of …, 2022 - Springer
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of
neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous …

Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis

LC Strazzulla, EHC Wang, L Avila, KL Sicco… - Journal of the American …, 2018 - Elsevier
Alopecia areata (AA) is a common, inflammatory, nonscarring type of hair loss. Significant
variations in the clinical presentation of AA have been observed, ranging from small, well …

[HTML][HTML] Emerging topical and systemic JAK inhibitors in dermatology

F Solimani, K Meier, K Ghoreschi - Frontiers in immunology, 2019 - frontiersin.org
Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

JAK inhibitors in dermatology: the promise of a new drug class

W Damsky, BA King - Journal of the American Academy of Dermatology, 2017 - Elsevier
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–
signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling …

Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib

S Ferreira, E Guttman-Yassky, T Torres - American journal of clinical …, 2020 - Springer
Atopic dermatitis is a common, chronic, immune-mediated disease associated with several
comorbidities. Elevated levels of T helper (Th) 2, Th22, and also some Th1 and Th17 …

[HTML][HTML] Psoriasis: a STAT3-centric view

E Calautti, L Avalle, V Poli - International journal of molecular sciences, 2018 - mdpi.com
Signal Transducer and Activator of Transcription (STAT) 3 has recently emerged as a key
player in the development and pathogenesis of psoriasis and psoriatic-like inflammatory …

Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors

K Welsch, J Holstein, A Laurence… - European journal of …, 2017 - Wiley Online Library
For most inflammatory skin diseases topical glucocorticosteroids and traditional oral
immunosuppressive drugs remain the principle treatment choices, but this has started to …

Emerging therapies for atopic dermatitis: JAK inhibitors

DG Cotter, D Schairer, L Eichenfield - Journal of the American Academy of …, 2018 - Elsevier
The Janus kinase–signal transducer and activator of transcription pathway is a conserved
master regulator of immunity and myeloproliferation. Advanced understanding of this …

Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre …

H Nakagawa, O Nemoto, A Igarashi… - British Journal of …, 2018 - academic.oup.com
Background JTE‐052 is a novel Janus kinase inhibitor presently under clinical development
for the topical treatment of atopic dermatitis (AD). Objectives To evaluate the efficacy and …

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

A Berekmeri, F Mahmood, M Wittmann… - Expert review of clinical …, 2018 - Taylor & Francis
Introduction: Psoriasis and psoriatic arthritis (PsA) are inflammatory immune-mediated
conditions which can cause considerable disability and reduced quality of life. Management …